ABIONYX Pharma

Share Issue/Capital Change • Jan 11, 2019

Monthly statement of total voting rights and shares forming the company's share capital

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Market: Euronext Paris, Compartment C ISIN code: FR0012616852

Date	Number of shares outstanding	Total voting rights
		Total gross (1)	Total net (2)
December 31, 2018	18,947,016	18,947,016	18,861,813

• (1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of allsharesto which voting rights are attached, including those for which voting rights have been suspended.
• (2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About Cerenis Therapeutics

Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies. CERENIS' expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy. CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development and several products in clinical phases.

Contacts: Cerenis info@cerenis.com Tel: +33 (0)5 62 24 09 49

NewCap Investors relations Emmanuel Huynh / Louis-Victor Delouvrier cerenis@newcap.eu Tel: +33 (0)1 44 71 98 53